BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 21702998)

  • 21. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
    Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
    Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
    Chambers SK; Gertz RE; Ivins CM; Kacinski BM
    Cancer; 1995 Apr; 75(7):1627-33. PubMed ID: 8826920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
    Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasminogen Activation System in Rectal Adenocarcinoma.
    Razik E; Kobierzycki C; Grzegrzolka J; Podhorska-Okolow M; Drag-Zalesinska M; Zabel M; Dziegiel P
    Anticancer Res; 2015 Nov; 35(11):6009-15. PubMed ID: 26504024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
    Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
    J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.
    Andres SA; Edwards AB; Wittliff JL
    J Clin Lab Anal; 2012 Feb; 26(2):93-103. PubMed ID: 22467324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor.
    Kotzsch M; Sieuwerts AM; Grosser M; Meye A; Fuessel S; Meijer-van Gelder ME; Smid M; Schmitt M; Baretton G; Luther T; Magdolen V; Foekens JA
    Breast Cancer Res Treat; 2008 Sep; 111(2):229-40. PubMed ID: 17952591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer.
    Luther T; Kotzsch M; Meye A; Langerholc T; Füssel S; Olbricht N; Albrecht S; Ockert D; Muehlenweg B; Friedrich K; Grosser M; Schmitt M; Baretton G; Magdolen V
    Thromb Haemost; 2003 Apr; 89(4):705-17. PubMed ID: 12669126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.
    Plebani M; Herszènyi L; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F
    Clin Exp Metastasis; 1997 Jul; 15(4):418-25. PubMed ID: 9219730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
    Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serine proteinase activation in esophageal cancer.
    Tang WH; Friess H; Kekis PB; Martignoni ME; Fukuda A; Roggo A; Zimmerman A; Büchler MW
    Anticancer Res; 2001; 21(4A):2249-58. PubMed ID: 11724279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.
    Sato S; Kopitz C; Grismayer B; Beaufort N; Reuning U; Schmitt M; Luther T; Kotzsch M; Krüger A; Magdolen V
    Breast Cancer Res Treat; 2011 Jun; 127(3):649-57. PubMed ID: 20635136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
    McGarvey TW; Kariko K; Barnathan ES; Thomas J; Malkowicz SB
    Int J Oncol; 1998 Jan; 12(1):175-80. PubMed ID: 9454902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
    Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S; Vrhovec I; Svetic B; Cufer T
    Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
    Foca C; Moses EK; Quinn MA; Rice GE
    Gynecol Oncol; 2000 Nov; 79(2):244-50. PubMed ID: 11063652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.
    Borgfeldt C; Bendahl PO; Gustavsson B; Långström E; Fernö M; Willén R; Grenman S; Casslén B
    Int J Cancer; 2003 Nov; 107(4):658-65. PubMed ID: 14520707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells.
    Moreau M; Mourah S; Dosquet C
    Int J Cancer; 2011 Mar; 128(6):1280-92. PubMed ID: 20473943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
    Friess H; Duarte R; Kleeff J; Fukuda A; Tang WH; Graber H; Schilling M; Zimmermann A; Korc M; Büchler MW
    Surgery; 1998 Jul; 124(1):79-86. PubMed ID: 9663255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.